Cost-effectiveness of omalizumab for the treatment of Chronic Spontaneous Urticaria.

CONCLUSIONS: Omalizumab is cost-effective compared to SoC. The outcomes of this study were used to establish omalizumab as third-line treatment in the Dutch treatment guidelines for CSU. This article is protected by copyright. All rights reserved. PMID: 29476533 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29476533?dopt=Abstract

Source: The British Journal of Dermatology - February 24, 2018 Category: Dermatology Authors: Kanters TA, Thio HB, Hakkaart L Tags: Br J Dermatol Source Type: research